Breast Cancer Clinical Trial
Official title:
A Randomized Phase II Study Of CMF Alone And In Combination With Anti c-erbB2 Antibody (Herceptin) In Women With c-erbB2 Positive Metastatic Breast Cancer
Verified date | March 2024 |
Source | European Organisation for Research and Treatment of Cancer - EORTC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Drugs used in chemotherapy such as cyclophosphamide, methotrexate, and fluorouracil use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with trastuzumab may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining combination chemotherapy with trastuzumab in treating women who have metastatic breast cancer.
Status | Completed |
Enrollment | 90 |
Est. completion date | February 2010 |
Est. primary completion date | June 2009 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 120 Years |
Eligibility | DISEASE CHARACTERISTICS: - Histologically confirmed metastatic breast cancer c-erbB2 positive (3+ overexpression by the HercepTest™ method) in the primary tumor or metastatic site - At least 1 unidimensionally measurable target lesion - At least 20 mm by conventional techniques OR - At least 10 mm by spiral CT scan - Lesions that have been irradiated in the preceding 3 months cannot be used as target lesions unless they have appeared or clearly progressed since prior irradiation - No bone lesions as the only target lesions - No contralateral breast cancer that is c-erbB2-positive or c-erbB2-negative/unknown, with status determined on a metastatic site - No CNS metastases - CT scan of brain and CSF cytology are required if neurologic symptoms are present - Hormone receptor status: - Any estrogen or progesterone receptor status PATIENT CHARACTERISTICS: Age: - 18 and over Sex: - Female Menopausal status: - Any status Performance status: - ECOG 0-2 Life expectancy: - Not specified Hematopoietic: - Neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin no greater than 1.25 times upper limit of normal (ULN) - Transaminases less than 2.5 times ULN (5 times ULN if liver metastases present) Renal: - For patients age 18 to 69: - Creatinine no greater than ULN - For patients age 70 and over: - Creatinine clearance normal Cardiovascular: - LVEF normal by MUGA or echocardiogram - No clinical heart failure Pulmonary: - No malignancy-associated dyspnea at rest - No requirement for supportive oxygen therapy Other: - Not pregnant or nursing - No other prior or concurrent malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or basal cell skin cancer - No psychological, familial, sociological, or geographical condition that would preclude compliance with study therapy and follow-up schedule PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior anti-c-erbB2 antibody, including trastuzumab (Herceptin®) - No other concurrent biologic therapy Chemotherapy: - No more than 1 prior chemotherapy regimen for metastatic breast cancer - Prior combination of cyclophosphamide, methotrexate, and fluorouracil (CMF) allowed in the adjuvant or metastatic setting only if the disease-free interval after completion of CMF was at least 12 months - Prior anthracyclines and/or taxanes allowed - At least 4 weeks since prior anthracyclines - No prior cumulative dose of doxorubicin more than 360 mg/m^2 - No prior cumulative dose of epirubicin more than 720 mg/m^2 - No prior cumulative dose of mitoxantrone more than 90 mg/m^2 - No other concurrent chemotherapy Endocrine therapy: - More than 2 weeks since prior hormonal therapy in the adjuvant or metastatic setting - No concurrent hormonal therapy Radiotherapy: - See Disease Characteristics - No concurrent radiotherapy Surgery: - Not specified Other: - No other concurrent anticancer therapy or investigational drugs - No concurrent bisphosphonates started after study enrollment except for hypercalcemia |
Country | Name | City | State |
---|---|---|---|
Belgium | Ziekenhuis Netwerk Antwerpen Middelheim | Antwerp | |
Belgium | Institut Jules Bordet | Brussels | |
Belgium | Universitair Ziekenhuis Antwerpen | Edegem | |
Denmark | Herlev Hospital - University Hospital of Copenhagen | Copenhagen | |
Egypt | National Cancer Institute of Egypt | Cairo | |
France | Centre de Lutte Contre le Cancer Georges-Francois Leclerc | Dijon | |
Netherlands | Onze Lieve Vrouwe Gasthuis | Amsterdam | |
Netherlands | Leiden University Medical Center | Leiden | |
Netherlands | Nijmegen Cancer Center at Radboud University Medical Center | Nijmegen | |
Poland | Medical University of Gdansk | Gdansk | |
Serbia | Institute of Oncology and Radiology of Serbia | Belgrade | |
South Africa | Medical Oncology Centre of Rosebank | Johannesburg | |
United Kingdom | Western Infirmary | Glasgow | Scotland |
Lead Sponsor | Collaborator |
---|---|
European Organisation for Research and Treatment of Cancer - EORTC |
Belgium, Denmark, Egypt, France, Netherlands, Poland, Serbia, South Africa, United Kingdom,
Neskovic-Konstantinovic Z, Nooij M, Khaled H, et al.: Safety and efficacy of combined trastuzumab and CMF therapy in women with metastatic breast cancer: EORTC protocol 10995. [Abstract] J Clin Oncol 25 (Suppl 18): A-1040, 2007.
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical heart failure rate measured by New York Heart Association classification, LVEF, and ECG | from registration | ||
Primary | Response rate by RECIST | from registration | ||
Secondary | Duration of response by RECIST | from registration | ||
Secondary | Time to progression | from registration | ||
Secondary | Toxicity measured by CTC v2.0 | from registration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |